These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16815961)

  • 1. Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles.
    Kumar V; Locuson CW; Sham YY; Tracy TS
    Drug Metab Dispos; 2006 Oct; 34(10):1688-96. PubMed ID: 16815961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of CYP2C9 variants by dapsone.
    Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
    Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.
    McGinnity DF; Tucker J; Trigg S; Riley RJ
    Drug Metab Dispos; 2005 Nov; 33(11):1700-7. PubMed ID: 16081671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
    Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
    Hutzler JM; Hauer MJ; Tracy TS
    Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.
    Hummel MA; Locuson CW; Gannett PM; Rock DA; Mosher CM; Rettie AE; Tracy TS
    Mol Pharmacol; 2005 Sep; 68(3):644-51. PubMed ID: 15955872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
    Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
    Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.
    Wei L; Locuson CW; Tracy TS
    Mol Pharmacol; 2007 Nov; 72(5):1280-8. PubMed ID: 17686967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.
    Egnell AC; Eriksson C; Albertson N; Houston B; Boyer S
    J Pharmacol Exp Ther; 2003 Dec; 307(3):878-87. PubMed ID: 14557374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
    Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
    Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates.
    Marks BD; Thompson DV; Goossens TA; Trubetskoy OV
    J Biomol Screen; 2004 Aug; 9(5):439-49. PubMed ID: 15296644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
    Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
    Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 genotype as a predictor of drug disposition in humans.
    Lee CR
    Methods Find Exp Clin Pharmacol; 2004; 26(6):463-72. PubMed ID: 15349140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
    Dickmann LJ; Locuson CW; Jones JP; Rettie AE
    Mol Pharmacol; 2004 Apr; 65(4):842-50. PubMed ID: 15044613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes.
    Zhou Q; Matsumoto S; Ding LR; Fischer NE; Inaba T
    Life Sci; 2004 Sep; 75(18):2145-55. PubMed ID: 15325841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.